Age-related macular degeneration (ARMD) is the leading cause of severe vision loss in the developed world for people over 55 ...

It's normal for your eyes to change as you age, but these four expert-approved tips can help improve your eye health.

The FDA has cleared its first light-based therapy for dry age-related macular degeneration—which the agency described as ...

EyePoint Pharmaceuticals' lead product, EYP-1901, shows promising phase 2 results for wet AMD and DME. Read more about EYPT ...

Opthea is a clinical-stage biotech firm developing Sozinibercept, targeting VEGF-C and VEGF-D for wet AMD, with Phase 3 ...

Six clinical studies (A Study of rhuFAB V2 [Ranibizumab] in Subjects with Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration ... the patient's best earlier ...

The US Food and Drug Administration has FDA has granted marketing authorization to a form of light therapy as the first-ever ...

Opens in a new tab or window A novel gene therapy (ABBV-RGX-314) was well tolerated and reduced treatment burden in patients with bilateral neovascular age-related macular degeneration (AMD ...

HuidaGene Therapeutics gets US FDA clearance for CRISPR/Cas13 RNA-editing HG202 for macular degeneration: Shanghai Tuesday, November 5, 2024, 09:00 Hrs [IST] HuidaGene Therapeutic ...

SOL-1 expected to be fully randomized by YE 2024 with topline data expected in Q4 2025 Active clinical trial sites now enrolling patients d ...